Tango Therapeutics, Inc.
General ticker "TNGX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $477.7M (TTM average)
Tango Therapeutics, Inc. follows the US Stock Market performance with the rate: 55.7%.
Estimated limits based on current volatility of 4.1%: low 9.73$, high 10.56$
Factors to consider:
- Total employees count: 155 (+10.7%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Supply chain disruptions, Regulatory and compliance, Limited operating history, Product development risks, Market competition
- Current price 105.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.76$, 4.82$]
- 2025-12-31 to 2026-12-31 estimated range: [1.55$, 4.01$]
Financial Metrics affecting the TNGX estimates:
- Positive: with PPE of -2.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -39.36 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 63.04 <= 63.39
- Positive: Investing cash flow per share per price, % of 25.78 > -0.66
Short-term TNGX quotes
Long-term TNGX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $24.86MM | $36.53MM | $42.07MM |
| Operating Expenses | $135.93MM | $150.70MM | $187.66MM |
| Operating Income | $-111.07MM | $-114.17MM | $-145.59MM |
| Non-Operating Income | $2.95MM | $12.56MM | $15.50MM |
| R&D Expense | $105.91MM | $115.20MM | $143.92MM |
| Income(Loss) | $-108.12MM | $-101.61MM | $-130.09MM |
| Taxes | $0.05MM | $0.13MM | $0.21MM |
| Profit(Loss)* | $-108.18MM | $-101.74MM | $-130.30MM |
| Stockholders Equity | $249.48MM | $253.11MM | $199.52MM |
| Assets | $436.47MM | $402.57MM | $316.49MM |
| Operating Cash Flow | $-109.08MM | $-117.98MM | $-131.50MM |
| Capital expenditure | $7.69MM | $1.53MM | $0.75MM |
| Investing Cash Flow | $26.40MM | $41.43MM | $86.13MM |
| Financing Cash Flow | $1.61MM | $82.41MM | $47.66MM |
| Earnings Per Share** | $-1.23 | $-1.08 | $-1.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.